Letrozolo Pensa

Letrozole, the active ingredient in Letrozolo Pensa, is an aromatase inhibitor presented as an oral tablet for oral use. It reduces estrogen production and is employed in the treatment of estrogen receptor‑positive breast cancer in postmenopausal women and is indicated for patients with advanced disease.

GNH USA supplies Letrozolo Pensa as a licensed, GDP‑compliant international pharmaceutical product to hospitals, oncology centres, pharmacies and clinics worldwide. Our distribution network adheres to stringent quality standards and regulatory requirements, ensuring consistent product availability across multiple regions.

Letrozole is used in hormone‑dependent breast cancer management, targeting estrogen‑driven tumor growth.

- Early‑stage estrogen receptor‑positive breast cancer: improves disease‑free survival as adjuvant therapy. - Metastatic estrogen receptor‑positive breast cancer: delays progression in postmenopausal patients. - Neoadjuvant treatment of estrogen receptor‑positive breast cancer: reduces tumor size before surgery.

Letrozole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: transient episodes of increased skin temperature and sweating. - Joint and muscle pain: arthralgia or myalgia affecting daily activities. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: occasional throbbing pain. - Increased cholesterol: mild elevation of serum lipid levels.

Serious or Rare Side Effects: - Osteoporosis: decreased bone mineral density leading to fractures. - Severe liver injury: marked elevation of transaminases or hepatic failure. - Pulmonary embolism: sudden shortness of breath with chest pain. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Cardiovascular events: myocardial infarction or stroke.

When prescribing letrozole, clinicians should consider several safety and handling precautions.

- Monitor bone health: assess baseline density and consider calcium/vitamin D supplementation. - Check liver function: perform periodic hepatic enzyme tests. - Assess lipid profile: monitor cholesterol levels during therapy. - Evaluate cardiovascular risk: review history of thromboembolic disease. - Counsel on menopausal symptoms: discuss management of hot flashes and mood changes. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Letrozole can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce letrozole plasma levels. - Tamoxifen: concurrent use may antagonize therapeutic effect.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may enhance anticoagulant effect, requiring INR monitoring. - Cholesterol‑lowering agents (statins): possible increase in statin concentrations. - SSRIs/SNRIs: may exacerbate mood changes or fatigue. - Herbal supplements containing St. John’s wort: may lower letrozole exposure.